/LQDA
LQDA Stock - Liquidia Corporation
Healthcare|BiotechnologyNASDAQ
$38.09+4.07%
+$1.49 (+4.07%) • Jan 13
90
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+29.3%upside
Target: $49.25
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for LQDA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$37.71 – $38.47
TARGET (TP)$49.25
STOP LOSS$35.04
RISK/REWARD1:3.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.49
52W High$39.29
52W Low$11.26
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $14.00M | $17.49M | $15.94M | $12.85M | $739,628 |
| Gross Profit | $8.12M | $14.60M | $13.08M | $9.83M | $501,916 |
| Gross Margin | 58.0% | 83.5% | 82.1% | 76.5% | 67.9% |
| Operating Income | $-121,294,000 | $-73,384,000 | $-38,770,000 | $-33,797,000 | $-59,089,130 |
| Net Income | $-130,394,000 | $-78,502,000 | $-41,015,000 | $-34,579,000 | $-59,762,769 |
| Net Margin | -931.7% | -448.9% | -257.4% | -269.0% | -8080.1% |
| EPS | $-1.66 | $-1.21 | $-0.67 | $-0.70 | $-1.76 |
Company Overview
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
LQDABeat Rate
28%
Last 18 quarters
Avg Surprise
-16.1%
EPS vs Estimate
Beats / Misses
5/11
2 met exactly
Latest EPS
$-0.04
Q4 2025
EPS Surprise History
Q1 24
-82.6%
$-0.42vs$-0.23
Q2 24
-68.8%
$-0.54vs$-0.32
Q3 24
-5.7%
$-0.37vs$-0.35
Q4 24
0.0%
$-0.37vs$-0.37
Q1 25
-21.1%
$-0.46vs$-0.38
Q2 25
-7.1%
$-0.45vs$-0.42
Q3 25
-14.0%
$-0.49vs$-0.43
Q4 25
+91.1%
$-0.04vs$-0.45
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 18, 2026 | $0.08 | — | — | — |
Q4 2025 | Nov 3, 2025 | $-0.45 | $-0.04 | +91.1% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-0.43 | $-0.49 | -14.0% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.42 | $-0.45 | -7.1% | ✗ MISS |
Q1 2025 | Mar 19, 2025 | $-0.38 | $-0.46 | -21.1% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-0.37 | $-0.37 | 0.0% | = MET |
Q3 2024 | Aug 7, 2024 | $-0.35 | $-0.37 | -5.7% | ✗ MISS |
Q2 2024 | May 13, 2024 | $-0.32 | $-0.54 | -68.8% | ✗ MISS |
Q1 2024 | Mar 13, 2024 | $-0.23 | $-0.42 | -82.6% | ✗ MISS |
Q4 2023 | Nov 7, 2023 | $-0.20 | $-0.24 | -20.0% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-0.17 | $-0.36 | -111.8% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-0.18 | $-0.18 | 0.0% | = MET |
Q1 2023 | Mar 16, 2023 | $-0.17 | $-0.09 | +47.1% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-0.18 | $-0.14 | +22.2% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.24 | $-0.15 | +37.5% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.20 | $-0.30 | -50.0% | ✗ MISS |
Q1 2022 | Mar 17, 2022 | $-0.11 | $-0.23 | -109.1% | ✗ MISS |
Q4 2021 | Nov 3, 2021 | $-0.12 | $-0.14 | -16.7% | ✗ MISS |
Q3 2021 | Aug 10, 2021 | $-0.16 | $-0.13 | +18.8% | ✓ BEAT |
Latest News
Loading news...
Frequently Asked Questions about LQDA
What is LQDA's current stock price?
Liquidia Corporation (LQDA) is currently trading at $38.09 per share. The stock has moved +4.07% today.
What is the analyst price target for LQDA?
The average analyst price target for LQDA is $49.25, based on 1 analyst.
What sector is Liquidia Corporation in?
Liquidia Corporation operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is LQDA's market cap?
Liquidia Corporation has a market capitalization of $3.25 billion, making it a mid-cap company.
Does LQDA pay dividends?
No, Liquidia Corporation does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAGIO
Agios Pharmaceuticals, Inc.
$27.80
Mkt Cap: $1.6B
COGT
Cogent Biosciences, Inc.
$35.28
Mkt Cap: $5.0B
DNLI
Denali Therapeutics Inc.
$18.11
Mkt Cap: $2.8B
ETNB
89bio, Inc.
$14.84
Mkt Cap: $2.2B
GLPG
Galapagos N.V.
$33.25
Mkt Cap: $2.2B
GPCR
Structure Therapeutics Inc.
$77.92
Mkt Cap: $4.5B
IBRX
ImmunityBio, Inc.
$2.82
Mkt Cap: $2.8B
MESO
Mesoblast Limited
$17.76
Mkt Cap: $2.3B
OCUL
Ocular Therapeutix, Inc.
$10.43
Mkt Cap: $2.2B
RCUS
Arcus Biosciences, Inc.
$22.74
Mkt Cap: $2.5B
Explore stocks similar to LQDA for comparison